Hypofractionated Radiotherapy for Hematologic Malignancies during the COVID-19 Pandemic and Beyond

Hypofractionated Radiotherapy for Hematologic Malignancies during the COVID-19 Pandemic and Beyond

Purpose: Radiotherapy is integral in the management of hematological malignancies (HM). Standard radiotherapy dose fractionation regimens range between 20 and 50 Gy in 10–25 fractions over 2–5 weeks. This study presents the outcomes of patients with HM treated with hypofractionation radiotherapy (HF...

Full description

Bibliographic Details
Main Authors: Febin Antony, Arbind Dubey, Pamela Skrabek, Lung Fung Tsang, Pascal Lambert, Bohdan Bybel, Naseer Ahmed
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Current Oncology
Subjects:
lymphomas
hypofractionation
radiotherapy
Online Access:https://www.mdpi.com/1718-7729/31/1/25

Similar Items

Similar Items